75 related articles for article (PubMed ID: 30453386)
1. Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database.
Kim YA; Cho H; Lee N; Jung SY; Sim SH; Park IH; Lee S; Lee ES; Kim HJ
Cancer Med; 2018 Dec; 7(12):6084-6092. PubMed ID: 30453386
[TBL] [Abstract][Full Text] [Related]
2. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Ezaz G; Long JB; Gross CP; Chen J
J Am Heart Assoc; 2014 Feb; 3(1):e000472. PubMed ID: 24584736
[TBL] [Abstract][Full Text] [Related]
3. Association between heart failure and the incidence of cancer: a systematic review and meta-analysis.
Jaiswal V; Ang SP; Agrawal V; Hameed M; Saleeb MRA; Jaiswal A; Shah M; Lao NM; Chia JE; Paudel K; Gimelli A; Zacks J
Eur Heart J Open; 2023 Sep; 3(5):oead073. PubMed ID: 37818223
[TBL] [Abstract][Full Text] [Related]
4. Resolved Proteinuria May Attenuate the Risk of Heart Failure: A Nationwide Population-Based Cohort Study.
Chang Y; Kang MK; Park MS; Leem GH; Song TJ
J Pers Med; 2023 Nov; 13(12):. PubMed ID: 38138889
[TBL] [Abstract][Full Text] [Related]
5. Current Research Status and Implication for Further Study of Real-World Data on East Asian Traditional Medicine for Heart Failure: A Scoping Review.
Park J; Bak S; Chu H; Kang S; Youn I; Jun H; Sim D; Leem J
Healthcare (Basel); 2023 Dec; 12(1):. PubMed ID: 38200969
[TBL] [Abstract][Full Text] [Related]
6. Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies.
Wang T; Xing G; Fu T; Ma Y; Wang Q; Zhang S; Chang X; Tong Y
Int J Med Sci; 2024; 21(5):809-816. PubMed ID: 38617011
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.
Chu J; Tung L; Atallah I; Wei C; Cobleigh M; Rao R; Feinstein SB; Usha L; Banach K; Reiser J; Okwuosa TM
Cardiooncology; 2024 Jan; 10(1):3. PubMed ID: 38225669
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-induced cardiotoxicity and risk factors.
Belger C; Abrahams C; Imamdin A; Lecour S
Int J Cardiol Heart Vasc; 2024 Feb; 50():101332. PubMed ID: 38222069
[TBL] [Abstract][Full Text] [Related]
9. Water Extract of
Jeong Y; Lee SH; Lee J; Kim MS; Lee YG; Hwang JT; Choi SY; Yoon HG; Lim TG; Lee SH; Choi HK
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958893
[TBL] [Abstract][Full Text] [Related]
10. Exosomal circRNA RHOT1 promotes breast cancer progression by targeting miR-204-5p/ PRMT5 axis.
Jiang W; Yu Y; Ou J; Li Y; Zhu N
Cancer Cell Int; 2023 Nov; 23(1):260. PubMed ID: 37924099
[TBL] [Abstract][Full Text] [Related]
11. Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer.
Xiong D; Yang J; Li D; Wang J
Cardiovasc Toxicol; 2023 Oct; 23(9-10):329-348. PubMed ID: 37684436
[TBL] [Abstract][Full Text] [Related]
12. Integrated High-Throughput Bioinformatics (Microarray, RNA-Seq, and RNA Interaction) and qRT-PCR Investigation of
Azadeh M; Salehzadeh A; Ghaedi K; Talesh Sasani S
Adv Biomed Res; 2023; 12():120. PubMed ID: 37434942
[TBL] [Abstract][Full Text] [Related]
13. Loss of DNA repair mechanisms in cardiac myocytes induce dilated cardiomyopathy.
Henpita C; Vyas R; Healy CL; Kieu TL; Gurkar AU; Yousefzadeh MJ; Cui Y; Lu A; Angelini LA; O'Kelly RD; McGowan SJ; Chandrasekhar S; Vanderpool RR; Hennessy-Wack D; Ross MA; Bachman TN; McTiernan C; Pillai SPS; Ladiges W; Lavasani M; Huard J; Beer-Stolz D; St Croix CM; Watkins SC; Robbins PD; Mora AL; Kelley EE; Wang Y; O'Connell TD; Niedernhofer LJ
Aging Cell; 2023 Apr; 22(4):e13782. PubMed ID: 36734200
[TBL] [Abstract][Full Text] [Related]
14. Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review.
Philip LJ; Findlay SG; Gill JH
Int J Cardiol Cardiovasc Risk Prev; 2022 Dec; 15():200153. PubMed ID: 36573186
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of Ferroptosis-Related lncRNAs as Prognosis and Diagnosis Biomarkers for Breast Cancer.
Yao ZY; Xing C; Cai S; Xing XL
Biomed Res Int; 2022; 2022():2390764. PubMed ID: 36303582
[TBL] [Abstract][Full Text] [Related]
16. Cardiometabolic Comorbidities in Cancer Survivors:
Zullig LL; Sung AD; Khouri MG; Jazowski S; Shah NP; Sitlinger A; Blalock DV; Whitney C; Kikuchi R; Bosworth HB; Crowley MJ; Goldstein KM; Klem I; Oeffinger KC; Dent S
JACC CardioOncol; 2022 Jun; 4(2):149-165. PubMed ID: 35818559
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis.
Zhang M; Yang H; Xu C; Jin F; Zheng A
Front Oncol; 2022; 12():899782. PubMed ID: 35785172
[TBL] [Abstract][Full Text] [Related]
18. High Sensitivity Troponin T as Complementary Modality for Determining Doxorubicin Regimen Cardiotoxicity in Non-Hodgkin Lymphoma Patients.
Prayogo AA; Suryantoro SD; Savitri M; Hendrata WM; Wijaya AY; Pikir BS
Adv Pharm Bull; 2022 Jan; 12(1):163-168. PubMed ID: 35517883
[No Abstract] [Full Text] [Related]
19. Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.
Wang Y; Wang Y; Han X; Sun J; Li C; Adhikari BK; Zhang J; Miao X; Chen Z
Front Cardiovasc Med; 2022; 9():727487. PubMed ID: 35369296
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.
Nicoletto RE; Ofner CM
Cancer Chemother Pharmacol; 2022 Mar; 89(3):285-311. PubMed ID: 35150291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
